Significant events during the second quarter 2025

• In April, Nanexa announced that initial observations in the phase I study show that the 30 mg dose of NEX-22 has been well tolerated by patients with type 2 diabetes who have not previously received GLP-1 treatment.
• In April, Nanexa announced that Bridget Lacey, who has over 25 years of corporate and business development experience across the life sciences sector, had been appointed Chief Business Officer.
• In May, Nanexa announced that all pharmacokinetic (PK) samples from the final dose group, 30 mg of the Phase I study for NEX-22, had been analyzed. The results showed increased exposure in line with the dose escalation and further demonstrated a controlled and prolonged release of liraglutide, which supports a one-month depot of liraglutide.
• Nanexa announced in May that an agreement had been made with Applied Materials, Inc. to terminate their collaboration. As part of the agreement, Nanexa received USD 750,000.
• Nanexa announced in May that the results from the recently completed Phase I-study with NEX-22 had been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association) held in Chicago June 20-23.
• Nanexa announced in June that the company had entered an intensive period of international presence, with a particular focus on NEX-22. As part of the agreement, Nanexa received USD
• Nanexa announced in June that the poster titled “A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes” was presented by the renowned diabetes researcher Dr. Hans de Vries at the American Diabetes Association’s 85th Scientific Sessions. The poster, which presented all data, including the 30 mg NEX-22 dose cohort, was very well received, and there was significant interest in the first published clinical data with a once-monthly long-acting injection of a GLP-1 drug. A 30 mg dose of NEX-22 shows exposure for up to 36 days without significant gastrointestinal side effects. This is not only highly positive for NEX-22, but all other potential GLP-1/GIP formulations which make use of PharmaShell.

Significant events after the end of the period

• In August, Nanexa announced the signing of continuation of a feasibility agreement with a major pharmaceutical company to investigate PharmaShell® long-acting formulations in a multi-billion USD market.

Financial overview

1 April - 30 June 2025

• Turnover amounted to: TSEK 2,705 (5,657)
• Operating profit (EBIT) amounted to: TSEK -5,237 (-6,124)
• Profit after tax amounted to: TSEK -5,899 (-6,012)
• Earnings per share amounted to: SEK -0.04 (-0.04)
• Cash flow for the period amounted to: TSEK -8,953 (-6,529)
• Cash and cash equivalents at end of period: TSEK 40,263 (41,311)

1 January - 30 June 2025

• Turnover amounted to: TSEK 5,582 (13,411)
• Operating profit (EBIT) amounted to: TSEK -13,450 (-9,487)
• Profit after tax amounted to: TSEK -14,886 (-8,835)
• Earnings per share amounted to: SEK -0.10 (-0.07)
• Cash flow for the period amounted to: TSEK 29,971 (-23,857)
• Cash and cash equivalents at end of period: TSEK 40,263 (41,311)

Figures in brackets refer to the corresponding period in the previous year.

The entire report is available on the company’s website: https://nanexa.com/en/financial-reports/.

Report commentary, 27 August at 9:00am CET

A live commentary with CEO David Westberg will take place on August 27 at 9:00am via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat.

The report commentary will be available here.

The report comment will also be published on Nanexa's website afterwards.